Genmab shares rise 8% as AbbVie’s combination therapy confirms reduced risk of death

Bank of America Global Research raised its target price for ASML from 2,452 euros to 2,557 euros.

On October 6, Option Care Health (OPCH.O) shares surged 23.2% in pre-market trading to $28.79 after the Financial Times reported on Monday that McKesson (MCK.N) and private equity firm CD&R are close to reaching a deal to acquire OPCH for over $5 billion (including debt). McKesson declined to comment, while CD&R and Option Care have not immediately responded to Reuters' request for comment on Monday. According to data from London Stock Exchange Group (LSEG), OPCH had a market value of about $3.5 billion as of the previous trading day’s close. Analysts at William Blair said the valuation is “on the low side” for Option Care, but “quite attractive” for McKesson and CD&R. “We believe the reported premium of more than 20% over Monday’s closing price is slightly disappointing for Option Care, and would not be surprised if one (or more) competing bids emerge,” the broker added. As of the previous trading day, OPCH shares have fallen 26.7% year-to-date.

Scotiabank of Canada raised its price target for AbbVie (ABBV.US) from $280 to $320.

Shell (SHEL.US) CEO: Our current Middle East energy exports have recovered to over 80% of pre-conflict levels.